Utilization of 3D bioprinting technology in creating human tissue and organoid models for preclinical drug research – State-of-the-art

Frankowski, Joachim; Kurzątkowska, Matylda; Sobczak, Marcin; Piotrowska, Urszula

doi:10.1016/j.ijpharm.2023.123313

Cited by 15 publications

(3 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While in vivo testing is crucial for safety assessment, it carries several drawbacks, including the need for approval from animal ethics committees, high research costs, challenges in replicating human physiology, and lengthy protocols [ 87 , 88 , 89 , 90 , 91 , 92 ]. The ethical dilemma of using animals in preclinical testing has been a longstanding concern in pharmaceutics and medicine [ 93 ]. The question of improving the welfare of animals used in scientific research, known as the 3Rs (replacement, reduction, and refinement), was raised by researchers in the mid-twentieth century and continues to be relevant today [ 94 , 95 ].…”

Section: Discussionmentioning

confidence: 99%

“…The question of improving the welfare of animals used in scientific research, known as the 3Rs (replacement, reduction, and refinement), was raised by researchers in the mid-twentieth century and continues to be relevant today [ 94 , 95 ]. The use of animals in preclinical testing has increased with advancements in drug technology and research and development [ 93 ].…”

Section: Discussionmentioning

confidence: 99%

“…Currently, bioprinting is a rapidly developing field of biomaterial engineering. With opportunities to achieve scientific breakthroughs, bioprinting technology has found its place in preclinical studies, which will rapidly push the pharmaceutical and biomedical industries forward in the future [ 93 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

(3D) Bioprinting—Next Dimension of the Pharmaceutical Sector

Mihaylova,

Shopova,

Parahuleva

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

To create a review of the published scientific literature on the benefits and potential perspectives of the use of 3D bio-nitrification in the field of pharmaceutics. This work was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting meta-analyses and systematic reviews. The scientific databases PubMed, Scopus, Google Scholar, and ScienceDirect were used to search and extract data using the following keywords: 3D bioprinting, drug research and development, personalized medicine, pharmaceutical companies, clinical trials, drug testing. The data points to several aspects of the application of bioprinting in pharmaceutics were reviewed. The main applications of bioprinting are in the development of new drug molecules as well as in the preparation of personalized drugs, but the greatest benefits are in terms of drug screening and testing. Growth in the field of 3D printing has facilitated pharmaceutical applications, enabling the development of personalized drug screening and drug delivery systems for individual patients. Bioprinting presents the opportunity to print drugs on demand according to the individual needs of the patient, making the shape, structure, and dosage suitable for each of the patient’s physical conditions, i.e., print specific drugs for controlled release rates; print porous tablets to reduce swallowing difficulties; make transdermal microneedle patches to reduce patient pain; and so on. On the other hand, bioprinting can precisely control the distribution of cells and biomaterials to build organoids, or an Organ-on-a-Chip, for the testing of drugs on printed organs mimicking specified disease characteristics instead of animal testing and clinical trials. The development of bioprinting has the potential to offer customized drug screening platforms and drug delivery systems meeting a range of individualized needs, as well as prospects at different stages of drug development and patient therapy. The role of bioprinting in preclinical and clinical testing of drugs is also of significant importance in terms of shortening the time to launch a medicinal product on the market.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

(3D) Bioprinting—Next Dimension of the Pharmaceutical Sector

Mihaylova,

Shopova,

Parahuleva

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Direct 3D‐Bioprinting of hiPSC‐Derived Cardiomyocytes to Generate Functional Cardiac Tissues

Esser,

Anspach,

Muenzebrock

et al. 2023

Advanced Materials

View full text Add to dashboard Cite

Abstract3D‐bioprinting is a promising technology to produce human tissues as drug screening tool or for organ repair. However, direct printing of living cells has proven difficult. Here, we present a method to directly 3D‐bioprint human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes embedded in a collagen‐hyaluronic acid ink generating centimeter‐sized functional ring‐ and ventricle‐shaped cardiac tissues in an accurate and reproducible manner. The printed tissues contained hiPSC‐derived cardiomyocytes with well‐organized sarcomeres and exhibited spontaneous and regular contractions, which persisted for several months and were able to contract against passive resistance. Importantly, beating frequencies of the printed cardiac tissues could be modulated by pharmacological stimulation. This approach opens up new possibilities for generating complex functional cardiac tissues as models for advanced drug screening or as tissue grafts for organ repair or replacement.This article is protected by copyright. All rights reserved

show abstract

Evaluation of Anti‐inflammatory Activity of Garlic Extracts in 3D Bioprinted Skin Equivalents

Kang,

Jang,

Kim

et al. 2024

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Ongoing obstacles in preclinical drug testing have raised significant concerns within the pharmaceutical industry. Recently, utilizing the potential of three‐dimensional (3D) bioprinting offers a solution for creating tissue models for screening of the effectiveness and safety of new drugs. In this study, the anti‐inflammatory potential of garlic extracts is assessed, specifically N‐Benzyl‐N‐methyl‐dodecan‐1‐amine (BMDA), using a 3D bioprinted artificial skin model. Comprehensive physicochemical characterization and immunocytochemical analysis demonstrate that the 3D bioprinted skin model exhibits structures and functions resembling human skin. BMDA treatment in a prepared skin model reveals its capacity to mitigate H2O2‐induced oxidative stress and trigger anti‐inflammatory responses. Notably, BMDA reduces the expression of pro‐inflammatory cytokines and chemokines by downregulating NF‐κB and mitogen‐activated protein kinase inflammatory signaling pathways. In summary, our findings highlight the potential of an artificial skin model as a robust platform for the development of new drugs.

show abstract

Utilization of 3D bioprinting technology in creating human tissue and organoid models for preclinical drug research – State-of-the-art

Cited by 15 publications

References 142 publications

(3D) Bioprinting—Next Dimension of the Pharmaceutical Sector

(3D) Bioprinting—Next Dimension of the Pharmaceutical Sector

Direct 3D‐Bioprinting of hiPSC‐Derived Cardiomyocytes to Generate Functional Cardiac Tissues

Evaluation of Anti‐inflammatory Activity of Garlic Extracts in 3D Bioprinted Skin Equivalents

Contact Info

Product

Resources

About